203 related articles for article (PubMed ID: 37724378)
1. Tezepelumab: an anti-thymic stromal lymphopoietin monoclonal antibody for the treatment of asthma.
Shinkai M; Yabuta T
Immunotherapy; 2023 Dec; 15(17):1435-1447. PubMed ID: 37724378
[TBL] [Abstract][Full Text] [Related]
2. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option?
Menzies-Gow A; Wechsler ME; Brightling CE
Respir Res; 2020 Oct; 21(1):268. PubMed ID: 33059715
[TBL] [Abstract][Full Text] [Related]
3. Thymic Stromal Lymphopoietin and Tezepelumab in Airway Diseases: From Physiological Role to Target Therapy.
Bagnasco D; De Ferrari L; Bondi B; Candeliere MG; Mincarini M; Riccio AM; Braido F
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892164
[TBL] [Abstract][Full Text] [Related]
4. Current summary of clinical studies on anti-TSLP antibody, Tezepelumab, in asthma.
Kurihara M; Kabata H; Irie M; Fukunaga K
Allergol Int; 2023 Jan; 72(1):24-30. PubMed ID: 36470789
[TBL] [Abstract][Full Text] [Related]
5. Positioning of Tezepelumab in Severe Asthma.
Miralles-López JC; Antolín-Amérigo D; García-Moguel I; Domínguez-Ortega J; Delgado-Romero J; Quirce S
J Investig Allergol Clin Immunol; 2024 Feb; 34(1):1-11. PubMed ID: 37812191
[TBL] [Abstract][Full Text] [Related]
6. Tezepelumab: a novel biological therapy for the treatment of severe uncontrolled asthma.
Marone G; Spadaro G; Braile M; Poto R; Criscuolo G; Pahima H; Loffredo S; Levi-Schaffer F; Varricchi G
Expert Opin Investig Drugs; 2019 Nov; 28(11):931-940. PubMed ID: 31549891
[No Abstract] [Full Text] [Related]
7. Tezepelumab for asthma.
Nolasco S; Pelaia C; Scioscia G; Campisi R; Crimi C
Drugs Today (Barc); 2022 Dec; 58(12):591-603. PubMed ID: 36651067
[TBL] [Abstract][Full Text] [Related]
8. Tezepelumab for Severe Asthma: One Drug Targeting Multiple Disease Pathways and Patient Types.
Panettieri R; Lugogo N; Corren J; Ambrose CS
J Asthma Allergy; 2024; 17():219-236. PubMed ID: 38524099
[TBL] [Abstract][Full Text] [Related]
9. Thymic stromal lymphopoietin receptor blockade reduces allergic inflammation in a cynomolgus monkey model of asthma.
Cheng DT; Ma C; Niewoehner J; Dahl M; Tsai A; Zhang J; Gonsiorek W; Apparsundaram S; Pashine A; Ravindran P; Jung J; Hang J; Allard J; Bitter H; Tribouley C; Narula S; Wilson S; Fuentes ME
J Allergy Clin Immunol; 2013 Aug; 132(2):455-62. PubMed ID: 23810153
[TBL] [Abstract][Full Text] [Related]
10. Targeting TSLP in Asthma.
Parnes JR; Molfino NA; Colice G; Martin U; Corren J; Menzies-Gow A
J Asthma Allergy; 2022; 15():749-765. PubMed ID: 35685846
[TBL] [Abstract][Full Text] [Related]
11. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma.
Gauvreau GM; Sehmi R; Ambrose CS; Griffiths JM
Expert Opin Ther Targets; 2020 Aug; 24(8):777-792. PubMed ID: 32567399
[TBL] [Abstract][Full Text] [Related]
12. Expression and Regulation of Thymic Stromal Lymphopoietin and Thymic Stromal Lymphopoietin Receptor Heterocomplex in the Innate-Adaptive Immunity of Pediatric Asthma.
Lin SC; Cheng FY; Liu JJ; Ye YL
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29670037
[TBL] [Abstract][Full Text] [Related]
13. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial.
Diver S; Khalfaoui L; Emson C; Wenzel SE; Menzies-Gow A; Wechsler ME; Johnston J; Molfino N; Parnes JR; Megally A; Colice G; Brightling CE;
Lancet Respir Med; 2021 Nov; 9(11):1299-1312. PubMed ID: 34256031
[TBL] [Abstract][Full Text] [Related]
14. The Impact of Tezepelumab in Uncontrolled Severe Asthma: A Systematic Review of Randomized Controlled Trials.
Roy P; Rafa ZI; Haque SN; Tasha T; Arko SB; Agrawal H; Razu MI; Parisapogu A; Maisha S; Siddique MA; Abbasi FK; Shama N; Dev Nath S; Ghosh AS; Quader F
Cureus; 2022 Dec; 14(12):e32156. PubMed ID: 36601189
[TBL] [Abstract][Full Text] [Related]
15. Anti-TSLP antibodies: Targeting a master regulator of type 2 immune responses.
Nakajima S; Kabata H; Kabashima K; Asano K
Allergol Int; 2020 Apr; 69(2):197-203. PubMed ID: 31974038
[TBL] [Abstract][Full Text] [Related]
16. Tezepelumab in patients with allergic and eosinophilic asthma.
Caminati M; Buhl R; Corren J; Hanania NA; Kim H; Korn S; Lommatzsch M; Martin N; Matucci A; Nasser SM; Pavord ID; Domingo C
Allergy; 2024 May; 79(5):1134-1145. PubMed ID: 38146651
[TBL] [Abstract][Full Text] [Related]
17. Investigational thymic stromal lymphopoietin inhibitors for the treatment of asthma: a systematic review.
Rogliani P; Manzetti GM; Bettin FR; D'Auria M; Calzetta L
Expert Opin Investig Drugs; 2024 Jan; 33(1):39-49. PubMed ID: 38206116
[TBL] [Abstract][Full Text] [Related]
18. CASCADE: a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of tezepelumab on airway inflammation in patients with uncontrolled asthma.
Emson C; Diver S; Chachi L; Megally A; Small C; Downie J; Parnes JR; Bowen K; Colice G; Brightling CE
Respir Res; 2020 Oct; 21(1):265. PubMed ID: 33050900
[TBL] [Abstract][Full Text] [Related]
19. Tezepelumab: A Potential New Biological Therapy for Severe Refractory Asthma.
Pelaia C; Pelaia G; Crimi C; Maglio A; Gallelli L; Terracciano R; Vatrella A
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922072
[TBL] [Abstract][Full Text] [Related]
20. Thymic stromal lymphopoietin and alarmins as possible therapeutical targets for asthma.
Salvati L; Maggi L; Annunziato F; Cosmi L
Curr Opin Allergy Clin Immunol; 2021 Dec; 21(6):590-596. PubMed ID: 34608100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]